{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:25:00Z","timestamp":1792787100064,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Zoetis Inc, Parsipanny, NJ, USA"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lokivetmab is an injectable anti\u2010canine\u2010\n                      <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                      \u201031 monoclonal antibody to treat clinical manifestations of atopic dermatitis (\n                      <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\n                      ) in dogs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To characterize the efficacy and safety of lokivetmab, and to demonstrate its noninferiority to ciclosporin under field conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>\n                      Dogs with chronic\n                      <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      = 274) were enrolled from 40 practices in Belgium, The Netherlands, France and Germany.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Animals were randomized (1:1) to oral ciclosporin (5 mg\/kg\/once daily) or monthly injectable lokivetmab (1\u20133.3 mg\/kg) for three months. Eighty one animals that successfully completed the comparative phase were enrolled in a continuation phase receiving lokivetmab for an additional six months. Owners assessed pruritus on a Visual Analog Scale, skin lesions were assessed by veterinary investigators with a Canine\n                      <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>\n                      Extent and Severity Index (\n                      <jats:styled-content style=\"fixed-case\">CADESI<\/jats:styled-content>\n                      \u201003) scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Lokivetmab was noninferior to ciclosporin for pruritus reduction on Day 28 (51.90% versus 43.72%). For Day 28\n                      <jats:styled-content style=\"fixed-case\">CADESI<\/jats:styled-content>\n                      \u201003 percentage reduction, noninferiority of lokivetmab (54.17) versus ciclosporin (56.86%) was not achieved. At none of the time points were mean\n                      <jats:styled-content style=\"fixed-case\">CADESI<\/jats:styled-content>\n                      \u201003 scores significantly different between groups. Continued efficacy towards pruritus and lesions was demonstrated in the continuation phase where 76.3% of animals (\n                      <jats:italic>n<\/jats:italic>\n                      = 45) were assessed as \u2018normal\u2019 for pruritus at study end. No abnormal health events associated with lokivetmab were observed during the initial three month phase (142 dogs) or during the subsequent six month phase (81 dogs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Lokivetmab at a minimum monthly dose of 1 mg\/kg provided quick onset (within one day) of a lasting effect in reducing pruritus and skin lesions with a good safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vde.12478","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T05:47:34Z","timestamp":1505368054000},"page":"593","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client\u2010owned dogs with atopic dermatitis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-7002","authenticated-orcid":false,"given":"Hilde","family":"Moyaert","sequence":"first","affiliation":[{"name":"VMRD Zoetis Belgium SA Mercuriusstraat 20 Zaventem 1930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Van Brussel","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Belgium SA Mercuriusstraat 20 Zaventem 1930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stasia","family":"Borowski","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Belgium SA Mercuriusstraat 20 Zaventem 1930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Escalada","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Belgium SA Mercuriusstraat 20 Zaventem 1930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Mahabir","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Inc. 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney R.","family":"Walters","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Inc. 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Stegemann","sequence":"additional","affiliation":[{"name":"VMRD Zoetis Belgium SA Mercuriusstraat 20 Zaventem 1930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/B0-72-160422-6\/50048-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(01)00346-4"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.2003.00335.x"},{"key":"e_1_2_7_5_1","first-page":"269","volume-title":"Plumb's Veterinary Drug Handbook","author":"Plumb DC","year":"2015"},{"key":"e_1_2_7_6_1","unstructured":"Atopica[Summary of Product Characteristics].Elanco Europe Ltd Basingstoke Hampshire UK.2016revision. Available at:http:\/\/www.vmd.defra.gov.uk\/ProductInformationDatabase\/SPC_Documents\/SPC_328729.doc. Accessed July 3 2017."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102471"},{"key":"e_1_2_7_8_1","unstructured":"Apoquel[Summary of Product Characteristics]. Zoetis Belgium SA Louvain\u2010la\u2010Neuve Belgium.2015revision. Available athttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/veterinary\/medicines\/002688\/vet_med_000280.jsp&mid=WC0b01ac058008d7a8. Accessed June 22 2017."},{"key":"e_1_2_7_9_1","first-page":"147","article-title":"Identification and characterization of ZTS\u201000103289, a monoclonal antibody neutralizing IL\u201031\u2010mediated pruritus, in beagle dogs","volume":"26","author":"Fleck TJ","year":"2015","journal-title":"Vet Dermatol"},{"key":"e_1_2_7_10_1","first-page":"145","article-title":"Laboratory dose titration efficacy study of ZTS\u201000103289, a caninized anti\u2010IL\u201031 monoclonal antibody, in a canine model of IL\u201031\u2010induced pruritus","volume":"26","author":"Walters RR","year":"2015","journal-title":"Vet Dermatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12376"},{"key":"e_1_2_7_12_1","first-page":"138","article-title":"Proof of concept efficacy and safety study of an anti\u2010IL\u201031 monoclonal antibody for the treatment of atopic dermatitis in client\u2010owned dogs","volume":"26","author":"Michels GM","year":"2015","journal-title":"Vet Dermatol"},{"key":"e_1_2_7_13_1","unstructured":"VICH\u2010GCP(International Co\u2010operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products Good Clinical Practice) June2000. Available at:http:\/\/www.vichsec.org\/guidelines\/pharmaceuticals\/pharma-efficacy\/good-clinical-practice.html. Accessed June 22 2017."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12186"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00758.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2007.00569.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.2003.00318.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2007.00616.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00728.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00668.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01098.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0514-6"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00925.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002432"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23473"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2002.221.370"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.2002.00283.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00784.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01088.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0147-54-8"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp946"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.03.013"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.380"},{"key":"e_1_2_7_38_1","first-page":"404","article-title":"Identification and characterization of anti\u2010canine interleukin\u201031 neutralizing monoclonal antibodies","volume":"25","author":"Bammert G","year":"2014","journal-title":"Vet Dermatol"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.023"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12366"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvde.12478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.12478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:32:10Z","timestamp":1695699130000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.12478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/vde.12478"],"URL":"https:\/\/doi.org\/10.1111\/vde.12478","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"2017-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}